Development of Robust Experimental Assay Methods (aDREAM) Conference (Jan 8-9)
Promega BioPharmaceutical Technology Center
5445 East Cheryl Parkway
Contact: Michael Hoffmann
The 5th annual aDREAM Conference will focus on “Assay Reproducibility, Replicability and Robustness”, a significant theme in drug discovery research.
This topic is of great interest due to its importance in the development of physiologically relevant, valid, reproducible and robust assays in drug discovery and in exploring new disease biology and target/pathway identification. (Seok et al. PNAS, 26 February 2013; Steward et al. Experimental Neurol. 233, 597-605,2012; Russel, Nature, 4 April 2013).
The aDream conference has attracted potential content providers for the Assay Guidance Manual (AGM) which is available on the National Center For Biotechnology Information (NCBI) Bookshelf. The AGM was originally published in 2005 as a resource provided by Eli Lilly & Company for drug discovery scientists on the NIH Chemical Genomics Center (NCGC) website. The AGM was prescient towards this year's aDREAM conference theme of the three “R’s”: reproducibility, reliability and robustness, via rigorous assay design, optimization and validation of both in vitro and in vivo assays employed in pre-clinical drug discovery.
The aDREAM conference generally attracts drug discovery scientists from all over the United States and overseas, with a conference agenda featuring leading scientists on screening technologies, assay development, detection instrumentation, reagent development, data acquisition and analysis for drug discovery and development. In addition, scientists attending the aDREAM conference have the opportunity to meet with an international group of editors of the AGM and leading scientific experts from academia, industry and government laboratories in drug discovery and development to provide suggestions for updating and improving the AGM’s content.